Literature DB >> 28189554

The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort.

Maximilian F Lang1, Mark D Tyson2, JoAnn Rudd Alvarez3, Tatsuki Koyama3, Karen E Hoffman4, Matthew J Resnick5, Matthew R Cooperberg6, Xiao-Cheng Wu7, Vivien Chen7, Lisa E Paddock8, Ann S Hamilton9, Mia Hashibe10, Michael Goodman11, Sheldon Greenfield12, Sherrie H Kaplan13, Antoinette Stroup14, David F Penson15, Daniel A Barocas2.   

Abstract

OBJECTIVE: To evaluate the influence of psychosocial factors such as prostate cancer (PCa) anxiety, social support, participation in medical decision-making (PDM), and educational level on patient decisions to discontinue PCa active surveillance (AS) in the absence of disease progression.
METHODS: The Comparative Effectiveness Analysis of Surgery and Radiation study is a prospective, population-based cohort study of men with localized PCa diagnosed in 2011-2012. PCa anxiety, social support, PDM, educational level, and patient reasons for discontinuing AS were assessed through patient surveys. A Cox proportional hazards model examined the relationship between psychosocial variables and time to discontinuation of AS.
RESULTS: Of 531 patients on AS, 165 (30.9%) underwent treatment after median follow-up of 37 months. Whereas 69% of patients cited only medical reasons for discontinuing AS, 31% cited at least 1 personal reason, and 8% cited personal reasons only. Patients with some college education discontinued AS significantly earlier (hazard ratio: 2.0, 95% confidence interval: 1.2, 3.2) than patients with less education. PCa anxiety, social support, and PDM were not associated with seeking treatment.
CONCLUSION: We found that 31% of men who choose AS for PCa discontinue AS within 3 years. Eight percent of men who sought treatment did so in the absence of disease progression. Education, but not psychosocial factors, seems to influence definitive treatment-seeking. Future research is needed to understand how factors unrelated to disease severity influence treatment decisions among patients on AS to identify opportunities to improve adherence to AS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28189554      PMCID: PMC5410889          DOI: 10.1016/j.urology.2016.12.063

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  29 in total

1.  A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial.

Authors:  Carol Kronenwetter; Gerdi Weidner; Elaine Pettengill; Ruth Marlin; Lila Crutchfield; Patricia McCormac; Caren J Raisin; Dean Ornish
Journal:  Cancer Nurs       Date:  2005 Mar-Apr       Impact factor: 2.592

2.  A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Authors:  Scott E Eggener; Alex Mueller; Ryan K Berglund; Raj Ayyathurai; Cindy Soloway; Mark S Soloway; Robert Abouassaly; Eric A Klein; Steven J Jones; Chris Zappavigna; Larry Goldenberg; Peter T Scardino; James A Eastham; Bertrand Guillonneau
Journal:  J Urol       Date:  2013-01       Impact factor: 7.450

3.  A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.

Authors:  Lionne D F Venderbos; Roderick C N van den Bergh; Monique J Roobol; Fritz H Schröder; Marie-Louise Essink-Bot; Chris H Bangma; Ewout W Steyerberg; Ida J Korfage
Journal:  Psychooncology       Date:  2014-08-20       Impact factor: 3.894

4.  The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor.

Authors:  D P Lubeck; M S Litwin; J M Henning; D M Stier; P Mazonson; R Fisk; P R Carroll
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

Review 5.  Active surveillance for prostate cancer: a systematic review of the literature.

Authors:  Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

6.  Patient and visit characteristics related to physicians' participatory decision-making style. Results from the Medical Outcomes Study.

Authors:  S H Kaplan; B Gandek; S Greenfield; W Rogers; J E Ware
Journal:  Med Care       Date:  1995-12       Impact factor: 2.983

7.  Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.

Authors:  Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson
Journal:  J Comp Eff Res       Date:  2013-07       Impact factor: 1.744

8.  Long-term functional outcomes after treatment for localized prostate cancer.

Authors:  Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson
Journal:  N Engl J Med       Date:  2013-01-31       Impact factor: 91.245

9.  Increasing use of observation among men at low risk for prostate cancer mortality.

Authors:  Chad R Ritch; Amy J Graves; Kirk A Keegan; Shenghua Ni; Jeffrey C Bassett; Sam S Chang; Matthew J Resnick; David F Penson; Daniel A Barocas
Journal:  J Urol       Date:  2014-09-06       Impact factor: 7.450

10.  The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.

Authors:  David M Latini; Stacey L Hart; Sara J Knight; Janet E Cowan; Phillip L Ross; Janeen Duchane; Peter R Carroll
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

View more
  9 in total

1.  Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.

Authors:  Netty Kinsella; Pär Stattin; Declan Cahill; Christian Brown; Anna Bill-Axelson; Ola Bratt; Sigrid Carlsson; Mieke Van Hemelrijck
Journal:  Eur Urol       Date:  2018-03-26       Impact factor: 20.096

2.  Primary Care Physician Perspectives on Low Risk Prostate Cancer Management: Results of a National Survey.

Authors:  Archana Radhakrishnan; Lauren P Wallner; Ted A Skolarus; Vahakn B Shahinian; Paul H Abrahamse; Michael D Fetters; Sarah T Hawley
Journal:  Urol Pract       Date:  2021-04-22

Review 3.  The LUGPA Alternative Payment Model for Initial Therapy of Newly Diagnosed Patients With Organ-confined Prostate Cancer: Rationale and Development.

Authors:  Deepak A Kapoor; Neal D Shore; Gary M Kirsh; Jonathan Henderson; Todd D Cohen; Kathleen Latino
Journal:  Rev Urol       Date:  2017

Review 4.  Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for Prostate Cancer: A Systematic Review.

Authors:  Glenda Kith; Sarah Lisker; Urmimala Sarkar; Jill Barr-Walker; Benjamin N Breyer; Nynikka R Palmer
Journal:  Eur Urol Oncol       Date:  2019-07-06

5.  Associations of multimorbidity and patient-reported experiences of care with conservative management among elderly patients with localized prostate cancer.

Authors:  Ryan M Fiano; Gregory S Merrick; Kim E Innes; Malcolm D Mattes; Traci J LeMasters; Chan Shen; Usha Sambamoorthi
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

6.  Psychological predictors of delayed active treatment following active surveillance for low-risk prostate cancer: The Patient REported outcomes for Prostate cARE prospective cohort study.

Authors:  Kathryn L Taylor; George Luta; Vasiliki Zotou; Tania Lobo; Richard M Hoffman; Kimberly M Davis; Arnold L Potosky; Tengfei Li; David Aaronson; Stephen K Van Den Eeden
Journal:  BJUI Compass       Date:  2021-12-14

7.  Impact of active surveillance for prostate cancer on the risk of depression and anxiety.

Authors:  Davidson Sypre; Géraldine Pignot; Rajae Touzani; Patricia Marino; Jochen Walz; Stanislas Rybikowski; Thomas Maubon; Nicolas Branger; Naji Salem; Julien Mancini; Gwenaelle Gravis; Marc-Karim Bendiane; Anne-Deborah Bouhnik
Journal:  Sci Rep       Date:  2022-07-28       Impact factor: 4.996

8.  Why do men with prostate cancer discontinue active surveillance for definitive treatment? A mixed methods investigation.

Authors:  Megan McIntosh; Melissa J Opozda; Michael O'Callaghan; Andrew D Vincent; Daniel A Galvão; Camille E Short
Journal:  Psychooncology       Date:  2022-05-18       Impact factor: 3.955

9.  Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study.

Authors:  Furaha Kariburyo; Yuexi Wang; I-Ning Elaine Cheng; Lisa Wang; David Morgenstern; Lin Xie; Eric Meadows; John Danella; Michael L Cher
Journal:  BMC Urol       Date:  2018-06-04       Impact factor: 2.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.